Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q1 2024
Top Holdings46 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
UNITED THERAPEUTICS CORP | 2.9M | $656.7M | 7.7% | $151.50 | +51.63% | 14 qtrssince 2020-Q4 | Unchanged 0 |
APELLIS PHARMACEUTICALS INC | 11.1M | $653.1M | 7.6% | $43.88 | +33.95% | 13 qtrssince 2021-Q1 | Unchanged 0 |
ASCENDIS PHARMA A/S | 4M | $599.6M | 7.0% | $123.04 | +22.86% | 12 qtrssince 2021-Q2 | Increased 66 |
AVI BIOPHARMA INC | 4.3M | $562.4M | 6.6% | $107.06 | +20.92% | 21 qtrssince 2019-Q1 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 1.9M | $519.2M | 6.1% | $150.17 | +77.83% | 21 qtrssince 2019-Q1 | Increased 64 |
ARGENX SE - ADR | 1.2M | $487.6M | 5.7% | $224.78 | +75.16% | 21 qtrssince 2019-Q1 | Increased 62 |
Krystal Biotech, Inc. | 2.6M | $454.7M | 5.3% | $85.59 | +107.88% | 10 qtrssince 2021-Q4 | Decreased 0 |
SPDR S&P BIOTECH ETF | 4.3M | $408M | 4.8% | $88.83 | +6.27% | 2 qtrssince 2023-Q4 | Decreased 0 |
BIOMARIN PHARMACEUTICAL INC | 4.4M | $381.2M | 4.4% | $87.08 | +0.30% | 21 qtrssince 2019-Q1 | Increased 59 |
AMICUS THERAPEUTICS INC | 27.4M | $322.8M | 3.8% | $11.07 | +6.42% | 21 qtrssince 2019-Q1 | Unchanged 0 |
CEREVEL THERAPEUTICS HLDNG I | 7.6M | $319.4M | 3.7% | — | — | 3 qtrssince 2023-Q3 | Unchanged 0 |
VIKING THERAPEUTICS INC | 3.6M | $294.4M | 3.4% | $82.00 | -59.52% | 1 qtr | New 87 |
ARROWHEAD PHARMACEUTICALS IN | 8.6M | $244.7M | 2.9% | $29.00 | -1.37% | 4 qtrssince 2023-Q2 | Increased 86 |
XENON PHARMACEUTICALS INC | 5.7M | $243.9M | 2.8% | $21.21 | +102.94% | 21 qtrssince 2019-Q1 | Unchanged 0 |
ALPINE IMMUNE SCIENCES INC | 5.8M | $228.9M | 2.7% | — | — | 1 qtr | New 80 |
VERA THERAPEUTICS INC | 5.3M | $227M | 2.6% | $43.12 | 0.00% | 1 qtr | New 80 |
IOVANCE BIOTHERAPEUTICS INC | 11.7M | $173.4M | 2.0% | $15.03 | -1.40% | 21 qtrssince 2019-Q1 | Increased 80 |
INTRA-CELLULAR THERAPIES INC | 2.5M | $171.3M | 2.0% | — | — | 2 qtrssince 2023-Q4 | Increased 54 |
KYMERA THERAPEUTICS INC | 3.9M | $156.3M | 1.8% | $30.08 | +33.63% | 11 qtrssince 2021-Q3 | Increased 50 |
| 5.8M | $148.7M | 1.7% | $24.04 | +6.14% | 16 qtrssince 2020-Q2 | Increased 78 |
Avoro Capital Advisors LLC manages $8.6B across 46 positions as of Q1 2024. Top holdings: UTHR (7.7%), APLS (7.6%), ASND (7.0%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 11 new positions, 7 exits, 15 increased. Top move: VKTX (NEW, conviction 87). Portfolio: $8.6B across 46 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer